What is the recommended treatment for shingles (herpes zoster)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Shingles (Herpes Zoster)

Start oral antiviral therapy within 72 hours of rash onset with acyclovir, valacyclovir, or famciclovir to reduce disease duration, acute pain, and risk of complications including postherpetic neuralgia. 1, 2, 3

Antiviral Therapy

First-Line Treatment Options

All three antivirals are equally effective and well-tolerated; choice depends primarily on dosing convenience 4, 5:

  • Acyclovir 800 mg orally 5 times daily for 7-10 days 1, 3, 6
  • Valacyclovir 1 g orally 3 times daily for 7 days 3, 4
  • Famciclovir 500 mg orally 3 times daily for 7 days 3, 4

Timing is critical: Antiviral therapy is most effective when initiated within 72 hours of rash onset, though treatment may still benefit patients presenting later, especially those with ongoing new vesicle formation or at high risk for complications 2, 5.

Urgent Indications for Antiviral Treatment

Systemic antiviral therapy is urgently indicated in the following populations 5:

  • All patients ≥50 years of age (highest risk for postherpetic neuralgia) 1, 3, 5
  • Herpes zoster ophthalmicus or any head/neck involvement (risk of vision loss and neurological complications) 5
  • Immunocompromised patients at any age (HIV-infected, transplant recipients, those on immunosuppressive therapy) 1, 5
  • Severe disease (extensive rash, disseminated disease, or visceral involvement) 1, 5

Special Populations

HIV-infected patients may require higher doses and longer duration 1:

  • Acyclovir 400 mg orally 3-5 times daily until clinical resolution 1
  • Consider IV acyclovir 5 mg/kg every 8 hours for severe cases 1
  • Monitor for acyclovir-resistant strains; if suspected, use foscarnet 40 mg/kg IV every 8 hours 1

Immunocompromised patients with CD4+ counts <200 cells/µL have the highest risk for dissemination and complications 1.

Pain Management

Adequate analgesia is essential and should be initiated concurrently with antiviral therapy 2, 5:

  • Acute pain: Appropriately dosed analgesics (including opioids if needed) combined with neuroactive agents such as amitriptyline 5
  • Adjunct corticosteroids may reduce acute pain duration but do not prevent postherpetic neuralgia and are not routinely recommended 5

Postherpetic Neuralgia Treatment

If pain persists ≥90 days after rash onset 3:

First-line agents 3, 6:

  • Gabapentin or pregabalin
  • Tricyclic antidepressants (amitriptyline, nortriptyline)
  • Long-acting opioids or tramadol

Second-line agents 6:

  • Topical lidocaine patches
  • Topical capsaicin cream

Common Pitfalls to Avoid

  1. Do not delay treatment waiting for laboratory confirmation—diagnosis is clinical based on the characteristic unilateral dermatomal vesicular rash 2, 3

  2. Do not use topical acyclovir—it is substantially less effective than oral therapy 1

  3. Do not withhold treatment in patients presenting after 72 hours if they have ongoing new vesicle formation, are immunocompromised, or have head/neck involvement 2, 5

  4. Do not assume younger patients (<50 years) with uncomplicated truncal zoster require treatment—this is only a relative indication unless other risk factors are present 5

  5. In HIV-infected patients on high-dose valacyclovir (8 g/day), be aware of potential hemolytic uremic syndrome or thrombotic thrombocytopenic purpura; use recommended doses for herpes zoster instead 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Recommendations for the management of herpes zoster.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007

Research

Herpes zoster guideline of the German Dermatology Society (DDG).

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.